Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBV RNA cohort study of sequential peginterferon alfa-2b in NA-treated chronic hepatitis B
ChiCTR2200066480Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jul 2022
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label trial of peginterferon alfa-2b in Chronic Hepatitis B (CHB) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: HBsAg negative rate at end of 48 weeks of treatment and HBsAb seroconversion rate at end of 48 weeks of treatment. Started Jul 2022; status: recruiting.
02
Drugs
peginterferon alfa-2b
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR2200066480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066480.